RecruitingPhase 1NCT05487599
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Studying Gaucher disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prevail Therapeutics
- Principal Investigator
- Sarah Neuhaus, DOPrevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
- Intervention
- LY3884961(genetic)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2031
Study locations (8)
- Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Duke University Health System, Durham, North Carolina, United States
- Lysosomal & Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States
- Westmead Hospital-Cnr Hawkesbury and Darcy Rds, Westmead, New South Wales, Australia
- Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil
- SphinCS Clinical Science for LSD, Höchheim, Germany
- Hospital Quironsalud Zaragoza, Paseo Mariano Renovales Sn, Zaragoza, Spain
- Royal Free Hospital NHS Trust, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05487599 on ClinicalTrials.govOther trials for Gaucher disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06528080A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher DiseaseShanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06545136Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)Spur Therapeutics
- ACTIVE NOT RECRUITINGNCT06488261Long Term Follow-Up for Safety of AVR-RD-02John Bernat
- RECRUITINGNANCT05992532GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple MyelomaFundación Española de Hematología y Hemoterapía
- RECRUITINGNANCT05843552Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher DiseaseUniversity of Minnesota
- RECRUITINGEARLY PHASE1NCT06272149An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher DiseaseXinhua Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGNCT05526664Omics Gaucher Study: Multiomic ApproachCENTOGENE GmbH Rostock
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04411654Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Prevail Therapeutics